Premium
Transgenic mice for conditional gene manipulation in astroglial cells
Author(s) -
Slezak Michal,
Göritz Christian,
Niemiec Aurore,
Frisén Jonas,
Chambon Pierre,
Metzger Daniel,
Pfrieger Frank W.
Publication year - 2007
Publication title -
glia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.954
H-Index - 164
eISSN - 1098-1136
pISSN - 0894-1491
DOI - 10.1002/glia.20570
Subject(s) - biology , transgene , genetically modified mouse , neuroscience , gene , computational biology , microbiology and biotechnology , genetics
Astrocytes are thought to exert diverse functions in the brain, but it has been difficult to prove this in vivo because of a scarcity of tools to manipulate these cells. Here, we report the generation of new transgenic mouse lines that allow for conditional gene ablation in astrocytes using the tamoxifen‐ (TAM‐) inducible CreER T2 /loxP system and bacterial artificial chromosome (BAC)‐based transgenesis. In adult transgenic mice, where CreER T2 expression is driven by the promoter of the sodium‐dependent glutamate/aspartate transporter (Glast/Slc1a3) or of connexin 30 (Cx30/Gjb6), intraperitoneal TAM‐injection induced Cre‐mediated recombination in astroglial cells throughout the brain. Targeting efficacies varied in a region‐specific manner from 20 to 90% as indicated by enzyme‐based reporter lines and immunohistochemical staining. In addition, the Glast‐line allowed to target retinal Müller cells and adult neural stem/progenitor cells in neurogenic regions of the adult brain. Transgenic mice expressing CreER T2 under the control of the apolipoprotein e (ApoE) or aquaporin 4 (Aqp4) promoter showed inducible recombination in different areas of the central nervous system (CNS) albeit at low levels. Transgenic lines showed TAM‐induced recombination in specific peripheral organs. These new mouse lines should help to further explore the relevance of astrocytes for brain function, as well as their contribution to pathological conditions because of aging, disease or injury. © 2007 Wiley‐Liss, Inc.